Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 72

1.

Plasma concentrations of the amyloid-β peptides in young volunteers: the influence of the APOE genotype.

Zimmermann R, Huber E, Schamber C, Lelental N, Mroczko B, Brandner S, Maler JM, Oberstein T, Szmitkowski M, Rauh M, Kornhuber J, Lewczuk P.

J Alzheimers Dis. 2014;40(4):1055-60. doi: 10.3233/JAD-132687.

PMID:
24577473
2.

Amyloid-β 1-42 levels are modified by apolipoprotein E ε4 in Creutzfeldt-Jakob disease in a similar manner as in Alzheimer's disease.

Varges D, Jung K, Gawinecka J, Heinemann U, Schmitz M, von Ahsen N, Krasnianski A, Armstrong VW, Zerr I.

J Alzheimers Dis. 2011;23(4):717-26. doi: 10.3233/JAD-2010-101527.

PMID:
21157024
3.

Plasma beta-amyloid and duration of Alzheimer's disease in adults with Down syndrome.

Prasher VP, Sajith SG, Mehta P, Zigman WB, Schupf N.

Int J Geriatr Psychiatry. 2010 Feb;25(2):202-7. doi: 10.1002/gps.2321.

4.

Apolipoprotein E, especially apolipoprotein E4, increases the oligomerization of amyloid β peptide.

Hashimoto T, Serrano-Pozo A, Hori Y, Adams KW, Takeda S, Banerji AO, Mitani A, Joyner D, Thyssen DH, Bacskai BJ, Frosch MP, Spires-Jones TL, Finn MB, Holtzman DM, Hyman BT.

J Neurosci. 2012 Oct 24;32(43):15181-92. doi: 10.1523/JNEUROSCI.1542-12.2012.

5.

Apolipoprotein E genotype regulates amyloid-beta cytotoxicity.

Wilhelmus MM, Otte-Höller I, Davis J, Van Nostrand WE, de Waal RM, Verbeek MM.

J Neurosci. 2005 Apr 6;25(14):3621-7.

6.

The Relationship Between Plasma Aβ Levels, Cognitive Function and Brain Volumetrics: Sydney Memory and Ageing Study.

Poljak A, Crawford JD, Smythe GA, Brodaty H, Slavin MJ, Kochan NA, Trollor JN, Wen W, Mather KA, Assareh AA, Ng PC, Sachdev PS.

Curr Alzheimer Res. 2016;13(3):243-55.

PMID:
26679856
7.

APOE genotype results in differential effects on the peripheral clearance of amyloid-beta42 in APOE knock-in and knock-out mice.

Sharman MJ, Morici M, Hone E, Berger T, Taddei K, Martins IJ, Lim WL, Singh S, Wenk MR, Ghiso J, Buxbaum JD, Gandy S, Martins RN.

J Alzheimers Dis. 2010;21(2):403-9. doi: 10.3233/JAD-2010-100141.

8.

Aβ amyloid, cognition, and APOE genotype in healthy older adults.

Lim YY, Ellis KA, Ames D, Darby D, Harrington K, Martins RN, Masters CL, Rowe C, Savage G, Szoeke C, Villemagne VL, Maruff P; AIBL Research Group.

Alzheimers Dement. 2013 Sep;9(5):538-45. doi: 10.1016/j.jalz.2012.07.004. Epub 2012 Nov 14.

PMID:
23159043
9.

CSF beta-amyloid 1-42 and tau in Tunisian patients with Alzheimer's disease: the effect of APOE epsilon4 allele.

Smach MA, Charfeddine B, Lammouchi T, Harrabi I, Ben Othman L, Dridi H, Bennamou S, Limem K.

Neurosci Lett. 2008 Aug 1;440(2):145-9. doi: 10.1016/j.neulet.2008.05.076. Epub 2008 May 24.

PMID:
18555606
10.

APOE epsilon 4 lowers age at onset and is a high risk factor for Alzheimer's disease; a case control study from central Norway.

Sando SB, Melquist S, Cannon A, Hutton ML, Sletvold O, Saltvedt I, White LR, Lydersen S, Aasly JO.

BMC Neurol. 2008 Apr 16;8:9. doi: 10.1186/1471-2377-8-9.

11.

Gene-environment interactions: lifetime cognitive activity, APOE genotype, and β-amyloid burden.

Wirth M, Villeneuve S, La Joie R, Marks SM, Jagust WJ.

J Neurosci. 2014 Jun 18;34(25):8612-7. doi: 10.1523/JNEUROSCI.4612-13.2014.

12.

The urokinase-type plasminogen activator polymorphism PLAU_1 is a risk factor for APOE-epsilon4 non-carriers in the Italian Alzheimer's disease population and does not affect the plasma Abeta(1-42) level.

Pesaresi M, Batelli S, Prato F, Polito L, Lovati C, Scarpini E, Quadri P, Mariani C, Albani D, Forloni G.

Neurobiol Dis. 2007 Mar;25(3):609-13. Epub 2006 Dec 15.

PMID:
17174555
13.

Apolipoprotein E-epsilon4 alleles in cerebral amyloid angiopathy and cerebrovascular pathology associated with Alzheimer's disease.

Premkumar DR, Cohen DL, Hedera P, Friedland RP, Kalaria RN.

Am J Pathol. 1996 Jun;148(6):2083-95.

14.

Association between amylin and amyloid-β peptides in plasma in the context of apolipoprotein E4 allele.

Qiu WQ, Wallack M, Dean M, Liebson E, Mwamburi M, Zhu H.

PLoS One. 2014 Feb 10;9(2):e88063. doi: 10.1371/journal.pone.0088063. eCollection 2014.

15.

Cerebrospinal fluid beta-amyloid1-42 and tau in control subjects at risk for Alzheimer's disease: the effect of APOE epsilon4 allele.

Sunderland T, Mirza N, Putnam KT, Linker G, Bhupali D, Durham R, Soares H, Kimmel L, Friedman D, Bergeson J, Csako G, Levy JA, Bartko JJ, Cohen RM.

Biol Psychiatry. 2004 Nov 1;56(9):670-6.

PMID:
15522251
16.

Cerebrospinal fluid markers for Alzheimer's disease over the lifespan: effects of age and the APOEε4 genotype.

Popp J, Lewczuk P, Frommann I, Kölsch H, Kornhuber J, Maier W, Jessen F.

J Alzheimers Dis. 2010;22(2):459-68. doi: 10.3233/JAD-2010-100561.

PMID:
21084733
17.

Accelerated decline in apolipoprotein E-epsilon4 homozygotes with Alzheimer's disease.

Craft S, Teri L, Edland SD, Kukull WA, Schellenberg G, McCormick WC, Bowen JD, Larson EB.

Neurology. 1998 Jul;51(1):149-53.

PMID:
9674794
18.

The influence of insulin infusion on the metabolism of amyloid β peptides in plasma.

Karczewska-Kupczewska M, Lelental N, Adamska A, Nikołajuk A, Kowalska I, Górska M, Zimmermann R, Kornhuber J, Strączkowski M, Lewczuk P.

Alzheimers Dement. 2013 Jul;9(4):400-5. doi: 10.1016/j.jalz.2012.01.013. Epub 2012 Oct 27.

PMID:
23110868
19.

Physical activity and amyloid-β plasma and brain levels: results from the Australian Imaging, Biomarkers and Lifestyle Study of Ageing.

Brown BM, Peiffer JJ, Taddei K, Lui JK, Laws SM, Gupta VB, Taddei T, Ward VK, Rodrigues MA, Burnham S, Rainey-Smith SR, Villemagne VL, Bush A, Ellis KA, Masters CL, Ames D, Macaulay SL, Szoeke C, Rowe CC, Martins RN.

Mol Psychiatry. 2013 Aug;18(8):875-81. doi: 10.1038/mp.2012.107. Epub 2012 Aug 14.

PMID:
22889922
20.

Genetic associations between cathepsin D exon 2 C-->T polymorphism and Alzheimer's disease, and pathological correlations with genotype.

Davidson Y, Gibbons L, Pritchard A, Hardicre J, Wren J, Tian J, Shi J, Stopford C, Julien C, Thompson J, Payton A, Thaker U, Hayes AJ, Iwatsubo T, Pickering-Brown SM, Pendleton N, Horan MA, Burns A, Purandare N, Lendon CL, Neary D, Snowden JS, Mann DM.

J Neurol Neurosurg Psychiatry. 2006 Apr;77(4):515-7.

Supplemental Content

Support Center